StockWatch
·
Biotechnology: Pharmaceutical Preparations
DelistingNov 20, 2026, 07:31 AM

NextCure Faces Nasdaq Delisting Warning; Merger Expected to Resolve Issue

AI Summary

NextCure, Inc. received a notice from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement. The company's equity of $5.5 million is below the $10 million minimum. NextCure has 45 days to submit a plan to regain compliance, with a deadline of January 4, 2027. The company expects its previously announced merger with Avere Therapeutics, Inc., anticipated in mid-December 2026, to resolve this issue. If the merger does not close before the grace period ends, NextCure intends to submit a compliance plan. The notice does not immediately affect the trading of its common stock.

Key Highlights

  • NextCure received a delisting warning from Nasdaq for failing to meet the minimum stockholders' equity requirement of $10 million.
  • The company's stockholders' equity was reported at $5.5 million as of September 30, 2026.
  • NextCure has until January 4, 2027, to submit a plan to regain compliance.
  • The expected completion of the merger with Avere Therapeutics in mid-December 2026 is anticipated to resolve the compliance issue.
  • The Nasdaq notice has no immediate impact on the trading of NextCure's common stock.